TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21360203

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HI-RT, 75% of one repetition maximum [1-RM])
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined HI-RT and low-intensity blood flow restriction training (CB-RT, twice-weekly LI-BFR and once-weekly HI-RT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LI-BFR, 30% 1-RM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HI-RT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined HI-RT and low-intensity blood flow restriction training (CB-RT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LI-BFR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nontraining control (CON)
Number of subjects: 40
Study: 19726310

Group type: EXPERIMENTAL
Intervention: Combined treatment with laparoscopy, endoscopic and digital subtraction angiography in addition to conventional treatment (group B)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 97
Study: 16780265

Group type: EXPERIMENTAL
Intervention: Betahistine treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (different drugs)
Number of subjects: 42
Study: 15496643

Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg plus fluoxetine 20 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: fluoxetine 20 mg plus desloratadine 5 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: desloratadine 5 mg plus placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: fluoxetine 20 mg plus placebo
Number of subjects: 54
Study: 11206942

Group type: EXPERIMENTAL
Intervention: Decision aid (tape and workbook)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 0
Study: 9438485

Group type: EXPERIMENTAL
Intervention: QID dosing of inhaled corticosteroids
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 5:30 PM dosing of inhaled corticosteroids
Number of subjects: 3

Group type: COMPARATOR
Intervention: 8 AM dosing of inhaled corticosteroids
Number of subjects: 3
Study: 8102538

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline alone (n = 8)
Number of subjects: 17
Study: 3315768

Group type: EXPERIMENTAL
Intervention: Mixture I (24.5 +/- 1.7 I.U. of isophane protamine insulin + 9.8 +/- 0.78 I.U. of short‐acting soluble insulin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mixture II (identical doses of insulin zinc suspension + soluble insulin)
Number of subjects: 12
Study: 31237805

Group type: EXPERIMENTAL
Intervention: PSYCHLOPS Questionnaire
Number of subjects: 867

Group type: COMPARATOR
Intervention: Conventional, nomothetic measures
Number of subjects: 867
Study: 29563133

Group type: EXPERIMENTAL
Intervention: Recreational physical activity at least several times a month
Number of subjects: 1992

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 1992
Study: 29122264

Group type: EXPERIMENTAL
Intervention: Breathing techniques training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 26199083

Group type: EXPERIMENTAL
Intervention: Low-frequency 'inhibiting' off-line repetitive transcranial magnetic stimulation (rTMS) on the left dorsal prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 0
Study: 24159259

Group type: EXPERIMENTAL
Intervention: QVA149 (110 μg indacaterol/50 μg glycopyrronium)
Number of subjects: 193

Group type: COMPARATOR
Intervention: IND+GLY (150 μg indacaterol and 50 μg glycopyrronium)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: QVA149
Number of subjects: 193

Group type: COMPARATOR
Intervention: IND+GLY
Number of subjects: 193
Study: 21145201

Group type: EXPERIMENTAL
Intervention: History of depression or active depressive symptoms
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Preferences for mechanical ventilation (MV)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Preferences for cardiopulmonary resuscitation (CPR)
Number of subjects: 376
Study: 17987059

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with BDNF Val66Met polymorphism
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 196
Study: 16510466

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15107368

Group type: EXPERIMENTAL
Intervention: Exercise therapy (active mobilisation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Collar therapy (cervical orthosis)
Number of subjects: 200
Study: 11454106

Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg bid
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 9735623

Group type: EXPERIMENTAL
Intervention: Mechanical treatment with taping and orthoses
Number of subjects: 103

Group type: COMPARATOR
Intervention: Anti-inflammatory treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Accommodative treatment
Number of subjects: 103
Study: 7986837

Group type: COMPARATOR
Intervention: Conventional CT technique, CM volume 150 ml of Ultravist 300 (30 ml at a flow rate of 1.5 ml/s, remaining 120 ml at 0.5 ml/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dynamic CT technique, CM volume 100 ml (200 ml at a flow rate of 2 ml/s and 80 ml at 0.5 ml/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spiral CT technique, CM dosage of 50 ml (30 ml at a flow rate of 2 ml/s and 20 ml at 0.7 ml/s)
Number of subjects: 60
Study: 3281618

Group type: EXPERIMENTAL
Intervention: 100 mg of atenolol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 150 mg of metoprolol tartrate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31352829

Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban regimen (60/30 mg)
Number of subjects: 19679

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 19679
Study: 28501319

Group type: EXPERIMENTAL
Intervention: Urinary 3‐phenoxybenzoic acid (3‐PBA) levels
Number of subjects: 305
Study: 25640526

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (COG REM) with social skills training (SST) for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Computer skills training with social skills training (SST)
Number of subjects: 64
Study: 23809273

Group type: EXPERIMENTAL
Intervention: Stereoscopic optic disc photographs
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement
Number of subjects: 109
Study: 21612945

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate cloths
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shower with soap and water
Number of subjects: 100
Study: 18028460

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus paracasei Lpc‐37, Lactobacillus acidophilus 74‐2, and Bifidobacterium animalis subsp. lactis DGCC 420
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probiotic drink
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16530506

Group type: EXPERIMENTAL
Intervention: Biofeedback (5 weekly sessions)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laxatives (polyethylene glycol 14.6‐29.2 g/day plus 5 weekly counseling sessions)
Number of subjects: 109
Study: 12716519

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Predictive method of comprehensive factors
Number of subjects: 150
Study: 10657405

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (antithrombotic treatment)
Number of subjects: 126
Study: 9301505

Group type: COMPARATOR
Intervention: Control (diet < 25% energy as fat)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wheat bran (25 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oat bran (64 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Processed wheat bran (Kellogg's All Bran, 38 g/day)
Number of subjects: 20
Study: 8326670

Group type: EXPERIMENTAL
Intervention: 20 gauge spinal needle
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 22 gauge spinal needle
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 23 gauge spinal needle
Number of subjects: 125

Group type: COMPARATOR
Intervention: 24 gauge spinal needle
Number of subjects: 125

Group type: COMPARATOR
Intervention: 25 gauge spinal needle
Number of subjects: 125
Study: 3548611

Group type: EXPERIMENTAL
Intervention: Imipenem (500 mg t.i.d.)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Netilmicin plus Clindamycin (600 mg t.i.d.)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 93

Group type: COMPARATOR
Intervention: Netilmicin plus Clindamycin
Number of subjects: 93
Study: 30239215

Group type: EXPERIMENTAL
Intervention: Ascending silhouette ordering
Number of subjects: 153

Group type: COMPARATOR
Intervention: Randomized figure ordering
Number of subjects: 153
Study: 30332312

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Social support among YBMSM living with HIV
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Stigma
Number of subjects: 474
Study: 27581113

Group type: EXPERIMENTAL
Intervention: Low-temperature atmospheric-pressure plasma (LTAPP) once every week for 8 consecutive weeks in addition to standard wound care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-temperature atmospheric-pressure plasma (LTAPP)
Number of subjects: 50
Study: 24178405

Group type: EXPERIMENTAL
Intervention: Rotational conjunctival flap with adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rotational conjunctival flap with 0.02% mitomycin C application (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rotational conjunctival flap alone (Group A)
Number of subjects: 90
Study: 23327586

Group type: EXPERIMENTAL
Intervention: M-0.2% CHX-diurnal (mouthrinse at 7:00 am)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: M-0.2% CHX-nocturnal (mouthrinse at 1:00 am)
Number of subjects: 10
Study: 20862715

Group type: EXPERIMENTAL
Intervention: Intravenous Salvia miltiorrhiza after surgery for 3 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous anisodamine after surgery for 3 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine wound care (Control group 1)
Number of subjects: 90
Study: 18606053

Group type: EXPERIMENTAL
Intervention: Polymyxin sulfate 7500 IU/neomycin sulfate 3500 IU/dexamethasone phosphate 0.1% (PN+Dx)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Polymyxin sulfate 7500 IU/neomycin sulfate 3500 IU (PN‐Dx)
Number of subjects: 338
Study: 15705013

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Active medication (stimulant and nonstimulant combined)
Number of subjects: 125
Study: 12546641

Group type: EXPERIMENTAL
Intervention: Atorvastatin, Simvastatin, Pravastatin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study: 10844830

Group type: EXPERIMENTAL
Intervention: High inspired oxygen fraction (FIO2) after CPB (FIO2 of 1.0, exposure time 70 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate inspired oxygen fraction (FIO2) after CPB (FIO2 of 0.35)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reduction of FIO2 from 1.0 to 0.6
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative day 1 measurements
Number of subjects: 20
Study: 8872838

Group type: EXPERIMENTAL
Intervention: Fitness intervention
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Home nutrition intervention
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Fitness programme
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Home nutrition programmes
Number of subjects: 1147

Group type: COMPARATOR
Intervention: School + home nutrition intervention
Number of subjects: 1147
Study: 1814603

Group type: EXPERIMENTAL
Intervention: Ranitidine infusion at 6.25 mg/hr
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine infusion at 10.0 mg/hr
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (6.25 mg/hr and 10.0 mg/hr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine infusion
Number of subjects: 12
Study: 6370586

Group type: EXPERIMENTAL
Intervention: OM-GA Cu
Number of subjects: 200

Group type: COMPARATOR
Intervention: Copper-T
Number of subjects: 200
Study: 29804469

Group type: EXPERIMENTAL
Intervention: Zinc Gluconate 233 mg/day plus vitamin E 400 IU/day for 6 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 54
Study: 30021566

Group type: EXPERIMENTAL
Intervention: Self-acceptance based psychosocial HIV prevention intervention (four group and six individual counseling sessions, including standard of care HIV/STI testing and counseling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care condition (HIV/STI testing and counseling alone)
Number of subjects: 0
Study: 27351719

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 17
Study: 24445534

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG +); n=151 patients
Number of subjects: 600

Group type: COMPARATOR
Intervention: No self-monitoring of blood glucose (SMBG -); n=149 patients
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Disclosure of HbA(1c) results (HbA(1c) +); n=158 patients
Number of subjects: 600

Group type: COMPARATOR
Intervention: No disclosure of HbA(1c) results (HbA(1c) -); n=142 patients
Number of subjects: 600
Study: 22734013

Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 245

Group type: COMPARATOR
Intervention: Paracentesis alone (Control)
Number of subjects: 245
Study: 19766403

Group type: EXPERIMENTAL
Intervention: PTSD+MDD
Number of subjects: 34

Group type: COMPARATOR
Intervention: PTSD-MDD
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 34
Study: 16963171

Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (AD, Admira/Admira Bond, VOCO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (DE, Definite/Etch & Prime 3.0, Dentsply)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bis-GMA-based composite (TC, Tetric-Ceram/Syntac, Ivoclar-Vivadent)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of all groups (AD, DE, TC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Surface roughness (AD and TC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Restoration size (> or = 3 surfaces)
Number of subjects: 32
Study: 16262965

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (without HRT)
Number of subjects: 0
Study: 12015517

Group type: COMPARATOR
Intervention: Outpatient treatment (single intramuscular injection of cefoxitin and oral doxycycline)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Inpatient treatment (intravenous cefoxitin and doxycycline)
Number of subjects: 831

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 831
Study: 11046204

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Xenon with isoflurane
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Xenon with sevoflurane
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: N2O with isoflurane
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: N2O with sevoflurane
Number of subjects: 162
Study: 9346384

Group type: EXPERIMENTAL
Intervention: EPO treatment (group II, n = 42)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Untreated anemic controls (group I, n = 31)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Untreated nonanemic controls (group III, n = 35)
Number of subjects: 108
Study: 1443808

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1 bolus, continuous infusion of 5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etomidate (0.3 mg.kg‐1 bolus, continuous infusion of 1.5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Number of subjects: 30
Study: 3989142

Group type: EXPERIMENTAL
Intervention: PEG-modified ragweed extract (10 weekly injections for group 1, 6 injections for group 2, followed by 10 injections before the second season)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PEG-modified ragweed extract
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study: 28891228

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 35
Study: 27182022

Group type: EXPERIMENTAL
Intervention: Overcoming Compassion Fatigue Program (5 weekly 80-minute sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 32
Study: 24236767

Group type: EXPERIMENTAL
Intervention: Monocular presentation of images to the same or different eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocular presentation of images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocular mechanisms
Number of subjects: 0
Study: 22515588

Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy alone (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy with psoralen gel (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy with calcipotriol ointment (Group 3)
Number of subjects: 30
Study: 20447203

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 24
Study: 18805053

Group type: EXPERIMENTAL
Intervention: Home Monitoring analysis
Number of subjects: 620

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 620
Study: 15959784

Group type: EXPERIMENTAL
Intervention: High molecular weight hyaluronan (hylan G-F 20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lower molecular weight hyaluronan
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: COMPARATOR
Intervention: All groups (HA and placebo)
Number of subjects: 59
Study: 12676890

Group type: EXPERIMENTAL
Intervention: Risperidone (1 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: d-Amphetamine (0, 2.5, 5, 10, and 15 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Risperidone (0 mg)
Number of subjects: 8
Study: 11147984

Group type: EXPERIMENTAL
Intervention: Home-based primary care (n=981)
Number of subjects: 1966

Group type: COMPARATOR
Intervention: Customary VA and private sector care (n=985)
Number of subjects: 1966
Study: 8871795

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (16 individual sessions over 4 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting list control (no treatment for 4 months)
Number of subjects: 32
Study: 1499947

Group type: EXPERIMENTAL
Intervention: Epinephrine (50 ng.kg‐1.min‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Phentolamine (5 mg/2 min followed by 500 micrograms/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol (5 mg/2 min followed by 80 micrograms/min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 29203153

Group type: EXPERIMENTAL
Intervention: Focused ultrasound unilateral subthalamotomy
Number of subjects: 10
Study: 27683840

Group type: EXPERIMENTAL
Intervention: EPAP 10 cmH2O
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EPAP 15 cmH2O
Number of subjects: 24
Study: 25025852

Group type: EXPERIMENTAL
Intervention: Ghavoot (34 g/dl) dissolved in 400 ml milk
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group received 400 ml milk
Number of subjects: 22
Study: 22075751

Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg/d for 3 weeks
Number of subjects: 864
Study: 20561856

Group type: EXPERIMENTAL
Intervention: Manual hyperinflation (MHI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation (VHI)
Number of subjects: 30
Study: 17716936

Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC
Number of subjects: 1780

Group type: COMPARATOR
Intervention: DTPw‐HBV/Hib
Number of subjects: 1780
Study: 15980845

Group type: EXPERIMENTAL
Intervention: Incisional drainage
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Opening of the pulp chamber drainage
Number of subjects: 112

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Penicillin-resistant bacteria presence
Number of subjects: 112
Study: 12897561

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol 5 to 8 mg.kg‐1.h‐1 and remifentanil 10 to 30 microg.kg‐1.h‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane (0.4‐1.0 vol%) and repetitive doses of 0.5 to 1 mg alfentanil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol-remifentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balanced anesthesia with isoflurane-alfentanil
Number of subjects: 90
Study: 10581665

Group type: EXPERIMENTAL
Intervention: Emergency treatment for acute exacerbations of obstructive pulmonary disease
Number of subjects: 50